Glimestar-M4 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 4 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glycemic control. This fixed-dose combination is designed for patients inadequately controlled on monotherapy or those requiring dual therapy to achieve optimal glycemic targets. The prolonged-release formulation ensures a steady plasma concentration, minimizing gastrointestinal side effects commonly associated with Metformin and improving patient compliance. Glimestar-M4 Forte Tablet PR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose levels. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Caution is advised in elderly patients and those with cardiovascular disease. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Dose adjustment may be necessary based on renal function and clinical response. Regular follow-up and laboratory assessments are essential to ensure safety and efficacy.